Eli Lilly’s first-quarter results underscore how branded pharma is betting on GLP-1 momentum and pipeline breadth

Eli Lilly’s first-quarter earnings, released April 30, helped set the tone for parts of the branded pharmaceutical sector as investors worked through another round of results. Lilly said revenue rose 56% to $19.8 billion, driven primarily by volume growth in its key marketed medicines, including the company’s GLP-1 portfolio for metabolic disease. In its earnings materials, the company tied the quarter’s performance to continued demand for Mounjaro and Zepbound, while acknowledging realized pricing pressures that partially offset the sales gains.

Along with the revenue increase, Lilly posted a sharp jump in earnings per share. Reported EPS climbed 170% to $8.26, while non-GAAP EPS increased 156% to $8.55. Lilly’s filings also show that both reported and non-GAAP results included acquired in-process research and development (IPR&D) charges, a type of accounting cost tied to past business development deals. By earnings-season standards, the company framed the quarter as a strong start to 2026 and emphasized that it was lifting guidance rather than merely meeting expectations.

Lilly raised its full-year guidance for 2026 as well. It updated revenue expectations to a range of $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00. Management said the guidance increase reflected stronger underlying business performance in the first quarter. In the same materials, the company pointed to the mix of growth drivers, including volume expansion, and noted that lower realized prices remained a recurring factor in reported results.

A central operating catalyst in Lilly’s quarter was regulatory progress tied to oral GLP-1 treatment. Lilly said the U.S. Food and Drug Administration approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. In Lilly’s description, Foundayo is the only approved GLP-1 pill for weight loss that can be taken any time of day without food and water restrictions, which the company said could widen access compared with older dosing requirements in the class.

Beyond the GLP-1 launch milestone, Lilly also highlighted multiple late-stage clinical updates across therapeutic areas. The company cited positive Phase 3 results for Foundayo in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk, and it referenced progress involving Jaypirca in combination with venetoclax and rituximab for certain relapsed or refractory blood cancers. Lilly also discussed treatment combinations that include Taltz and Zepbound for adults with psoriasis alongside obesity or overweight, and it pointed to retatrutide as a Phase 3 program in type 2 diabetes.

On the business-development side, Lilly said it entered agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics. The company did not characterize in these materials the expected financial impact of each deal at the time of reporting, but it described the acquisitions as part of an ongoing effort to invest in future growth while it continues scaling its marketed portfolio.

For branded pharmaceutical investors, the immediate takeaway is that Lilly is presenting a double-track earnings narrative: near-term sales momentum tied to volume, and longer-duration optionality from pipeline programs. The quarter also illustrates a pattern that has increasingly mattered in the sector’s earnings discussions, where demand growth can lift results even as pricing or realized-price dynamics remain a headwind.

Still, some items remain less clear in what Lilly disclosed publicly in the earnings materials. The company did not break out, in the press-release-style financial summary, how quickly Foundayo uptake will translate into incremental revenue, and it did not provide full detail on timing for additional approvals or how each acquisition will affect future cost structure. Also, while the Yahoo Finance roundup that flagged Lilly as a “leader” in branded pharmaceutical results is part of this editorial context, the exact comparison of “exciting” versus “less so” outcomes across other companies was not directly accessible for verification during this review due to access restrictions.

What to watch next includes Lilly’s rollout plans and any early prescribing and coverage indicates for Foundayo, additional clinical readouts as the company advances Phase 3 programs, and how the market interprets the relationship between volume growth and realized-price declines in subsequent quarters. For the broader branded pharma group, Lilly’s raised guidance may also set a reference point for whether peers can match growth without relying solely on GLP-1 demand.